However, the presence of anti-tumor immune cells led to the upregulation of inhibitory molecules, namely HLA-E, in cancer cells, suggesting that the latter can evade the tumor-suppressing immune response through NKG2A/HLA-E binding. This evidence concerns the gene KLRC1 and neoplasm.